Marinus Pharmaceuticals, Inc.
NASDAQ:MRNS
0.359 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 30.989 | 25.478 | 15.345 | 1.718 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 |
| Cost of Revenue
| 2.485 | 0.34 | 1.478 | 50.506 | 0.503 | 0.127 | 0.126 | 0.023 | 0.011 | 0 | 0 | 0 |
| Gross Profit
| 28.504 | 25.138 | 13.867 | -48.788 | -0.503 | -0.127 | -0.126 | -0.023 | -0.011 | 0 | 0 | 0.1 |
| Gross Profit Ratio
| 0.92 | 0.987 | 0.904 | -28.398 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 98.837 | 79.912 | 73.52 | 51.106 | 42.966 | 28.394 | 12.376 | 22.005 | 18.916 | 8.69 | 4.15 | 0.846 |
| General & Administrative Expenses
| 0 | 0 | 37.278 | 18.549 | 11.456 | 8.785 | 6.667 | 6.237 | 5.516 | 3.23 | 1.229 | 0.685 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 61.152 | 56.845 | 37.278 | 18.549 | 11.456 | 8.785 | 6.667 | 6.237 | 5.516 | 3.23 | 1.229 | 0.685 |
| Other Expenses
| -2.676 | 1.169 | 0.657 | -0.037 | -0.053 | -0.001 | -0.02 | -0.065 | -0.007 | 1.192 | 0.153 | 0.336 |
| Operating Expenses
| 159.989 | 137.926 | 110.798 | 69.655 | 54.422 | 37.179 | 19.043 | 28.242 | 24.432 | 11.92 | 5.351 | 1.526 |
| Operating Income
| -131.485 | -112.788 | -96.931 | -67.937 | -54.422 | -37.179 | -19.043 | -28.242 | -24.432 | -11.92 | -5.379 | -1.431 |
| Operating Income Ratio
| -4.243 | -4.427 | -6.317 | -39.544 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.307 |
| Total Other Income Expenses Net
| -11.458 | 96.361 | -1.845 | 0.462 | 0.301 | -0.001 | -0.02 | -0.065 | -0.007 | 1.192 | 0.153 | 0.336 |
| Income Before Tax
| -142.943 | -16.427 | -98.776 | -67.475 | -54.121 | -36.726 | -18.898 | -28.643 | -24.85 | -10.833 | -5.27 | -1.409 |
| Income Before Tax Ratio
| -4.613 | -0.645 | -6.437 | -39.275 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.085 |
| Income Tax Expense
| -1.538 | 3.389 | 2.884 | -0.833 | -0.354 | 0.453 | 0.013 | 0.399 | 0.468 | 1.309 | -0.028 | 0.657 |
| Net Income
| -141.405 | -19.816 | -101.66 | -66.642 | -53.767 | -36.726 | -18.898 | -28.643 | -24.85 | -10.833 | -5.27 | -1.409 |
| Net Income Ratio
| -4.563 | -0.778 | -6.625 | -38.79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.085 |
| EPS
| -2.63 | -0.51 | -2.77 | -2.44 | -3.95 | -3.59 | -3.21 | -5.88 | -6.66 | -7.04 | -2.61 | -0.7 |
| EPS Diluted
| -2.63 | -0.51 | -2.77 | -2.44 | -3.95 | -3.59 | -3.21 | -5.88 | -6.66 | -7.04 | -2.61 | -0.7 |
| EBITDA
| -130.934 | -5.755 | -96.194 | -67.937 | -54.144 | -36.599 | -18.739 | -28.156 | -24.364 | -10.711 | -5.169 | -1.07 |
| EBITDA Ratio
| -4.225 | -0.226 | -6.269 | -39.544 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10.699 |